NEW YORK (AP) _ TG Therapeutics Inc. (TGTX) on Tuesday reported a loss of $44.1 million in its second quarter.
The New York-based company said it had a loss of 59 cents per share.
The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 55 cents per share.
The biopharmaceutical company posted revenue of $38,000 in the period, which matched Street forecasts.
TG Therapeutics shares have climbed 46 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $12, a climb of 18 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TGTX at https://www.zacks.com/ap/TGTX